艾美疫苗(06660.HK):凍乾人用狂犬病在研疫苗內地藥物臨床試驗批准通知書
艾美疫苗(06660.HK)公布,公司之全資附屬公司寧波榮安生物藥業於近日取得國家藥品監督管理局藥品審評中心,關於凍乾人用狂犬病在研疫苗(無血清Vero細胞)的藥物臨床試驗批准通知書。集團計劃於2023年上半年啟動該在研疫苗的III期臨床試驗。
狂犬病是由狂犬病病毒引起的急性腦炎,通常通過受感染動物的叮咬進入人體。典型症狀包括傷口疼痛或極度不適、發熱、麻痺、神志不清、抽搐及怕水。狂犬病病毒的潛伏期一般為1至3個月。疾病發作後,通常在7至10天內死亡。狂犬病是一種高風險疾病,沒有有效的治療方法,但暴露於病毒後可以通過疫苗預防。Vero細胞是全球人用狂犬病疫苗的主流製造技術路線。(wl/k)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.